يعرض 921 - 940 نتائج من 9,427 نتيجة بحث عن 'significantly ((((linear decrease) OR (((we decrease) OR (mean decrease))))) OR (teer decrease))', وقت الاستعلام: 0.58s تنقيح النتائج
  1. 921

    GWAS analysis using Cluster 3 data (shown in S1 Fig). حسب Ke Li (106849)

    منشور في 2024
    "…(C) The corresponding non-synonymous (circles) amino acid changes that associate with increased or decreased viral copies. Data shown as means with 95% confidence intervals.…"
  2. 922

    GWAS analysis using Cluster 4 data (shown in S1 Fig). حسب Ke Li (106849)

    منشور في 2024
    "…(C) The corresponding synonymous (triangles) and non-synonymous (circles) amino acid changes that associate with increased or decreased viral copies. Data shown as means with 95% confidence intervals.…"
  3. 923
  4. 924

    GWAS analysis identifies several single nucleotide polymorphisms (SNPs) that are associated with the changes in viral copies. حسب Ke Li (106849)

    منشور في 2024
    "…(C) The corresponding synonymous (triangles) and non-synonymous (circles) amino acid changes that associate with increased or decreased viral copies. Data shown as means with 95% confidence intervals. …"
  5. 925
  6. 926

    GWAS analysis identifies several single nucleotide polymorphisms (SNPs) that are associated with the changes in viral copies. حسب Ke Li (106849)

    منشور في 2024
    "…(C) The corresponding synonymous (triangles) and non-synonymous (circles) amino acid changes that associate with increased or decreased viral copies. Data is shown as means with 95% confidence intervals. …"
  7. 927

    Flow chart of experimental protocol. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    "…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …"
  8. 928

    A representative ultrasound axis image. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    "…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …"
  9. 929
  10. 930
  11. 931

    Study flow chart. حسب Johannes Nairz (18010746)

    منشور في 2024
    الموضوعات:
  12. 932
  13. 933
  14. 934
  15. 935

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> حسب Chang Seok Han (21814121)

    منشور في 2025
    "…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …"
  16. 936
  17. 937
  18. 938

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  19. 939

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  20. 940

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"